Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors

Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors

Abstract Background Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation of therapy, yet, determining the expression status is most challenging i...

Full description

Bibliographic Details
Main Authors: Niklas Schäfer, Gerrit H. Gielen, Laurèl Rauschenbach, Sied Kebir, Andreas Till, Roman Reinartz, Matthias Simon, Pitt Niehusmann, Christoph Kleinschnitz, Ulrich Herrlinger, Torsten Pietsch, Björn Scheffler, Martin Glas
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Journal of Translational Medicine
Subjects:
Glioblastoma
Targeted therapy
Heterogeneity
EGFR
MLPA
Online Access:http://link.springer.com/article/10.1186/s12967-019-1846-y

Internet

http://link.springer.com/article/10.1186/s12967-019-1846-y

Similar Items